Altimmune opened lower at $1.90, compared with its previous close of $1.93. In the last trading session, the stock traded between $1.60 and $1.90. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Altimmune is now worth
$ 14.49
Resulting in a loss of
$ 85.51 (85.51%)
Note: Past profits do not guarantee future returns.
Rating from 3 Analysts
Today's Change
$-0.33 (-16.84%)
Day High
$1.90
Day Low
$1.60
Day Open
$1.90
Prev Close
$1.93
Volume
1,17,31,623
1W Return
-23.93%
1M Return
-37.43%
3M Return
-46.61%
6M Return
-48.06%
1Y Return
-62.50%
Market Cap ($ Mn)
312
PE Ratio
-
PB Ratio
1.28
PEG Ratio
-
ROE
-52.59%
ROCE
-51.00%
EPS (TTM)
$-0.12
1 Week
-23.93%
1 Month
-37.43%
3 Months
-46.61%
6 Months
-48.06%
9 Months
-65.33%
Altimmune publishes 48-week MASH data in Lancet journal
Altimmune published 48-week IMPACT Phase 2b results in The Lancet Gastroenterology & Hepatology. Pemvidutide showed significant reductions in liver fat, inflammation, and fibrosis vs placebo. Tolerability remained favorable with ~1% discontinuation rate due to adverse events. Data supports ongoing Phase 3 PERFORMA trial for MASH treatment.
TodayAltimmune pemvidutide cuts heavy drinking days 4.20 in Phase 2
Pemvidutide reduced heavy drinking days by 4.20 per week in Phase 2 AUD trial. Weight loss differential reached 9.1% compared to placebo group. Company plans FDA End-of-Phase 2 meeting in December for Phase 3 design.
3 days agoAltimmune to present new pemvidutide liver disease data at AASLD 2026
Altimmune presents new pemvidutide data at AASLD The Liver Meeting 2026 in Denver. IMPACT Phase 2b study shows reductions in liver stiffness, ELF score, liver fat, and ALT. Preclinical hamster model data demonstrates significant reduction in mean alcohol intake. Gastrointestinal adverse events were mild to moderate with no severe cases reported. Treatment discontinuations due to adverse events were lower for pemvidutide than placebo.
24 days agoAltimmune Q2 EPS $(0.12) beats $(0.15) estimate
Altimmune reported a Q2 net loss of $0.12 per share, beating the $(0.15) consensus by 20%. The result marks a 55.56% improvement in per-share losses versus the prior year. Strong interest income from a recent capital raise offset higher R&D and G&A costs.
3mo agoAltimmune's pemvidutide cuts heavy drinking days in Phase 2 AUD trial
Altimmune Inc. reported positive topline data from its RECLAIM Phase 2 trial of pemvidutide for alcohol use disorder, showing significant reductions in heavy drinking days and body weight. The stock rose over 11% following the announcement as the company plans to engage with the FDA.
3mo agoLeerink Partners initiates coverage on Altimmune with Outperform rating
Leerink Partners analyst Thomas Smith initiated coverage on Altimmune with an Outperform rating and a $10 price target, signaling a positive outlook for the stock.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Altimmune is now worth
$ 14.49
Resulting in a loss of
$ 85.51 (85.51%)
Note: Past profits do not guarantee future returns.
